Stock Highlights: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), CTI BioPharma Corp. (NASDAQ:CTIC), Groupon, Inc. (NASDAQ:GRPN), NVIDIA Corporation (NASDAQ:NVDA),

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) reported Net loss for the quarter was $18.1 million, or $0.50 loss per share; compared to a net loss of $20.6 million, or $0.69 loss per share in Q4 2014.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) belongs to Healthcare sector. Its weekly performance is -7.28%. On last trading day company shares ended up at $4.33. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) distance from 50-day simple moving average (SMA50) is -7.98%.

On 10 February, CTI BioPharma Corp. (NASDAQ:CTIC) provided an update regarding the clinical studies being conducted under the Company’s Investigational New Drug (“IND”) application for pacritinib.

CTI BioPharma Corp. (NASDAQ:CTIC) belongs to Healthcare sector. Its weekly performance is 33.62%. On last trading day company shares ended up at $0.67. CTI BioPharma Corp. (NASDAQ:CTIC) distance from 50-day simple moving average (SMA50) is 2.91%.

On 12 February, Groupon, Inc. (NASDAQ:GRPN) said that, its 4Q15 results indicate stability, particularly in North America. The region’s local gross billings and gross profits grew 6 percent year on year and 8 percent year on year, respectively, while gross profits in the EMEA declined 14 percent year on year due to lower than expected billings.

Groupon, Inc. (NASDAQ:GRPN) shares fell -0.47% in last trading session and ended the day at $4.20. GRPN Gross Margin is 44.40% and its return on assets is 1.00%. Groupon, Inc. (NASDAQ:GRPN) quarterly performance is 54.41%.

On 14 February, NVIDIA Corporation (NASDAQ:NVDA) are now in the testing and validation phase. The Pascal GPU architecture is certainly one of Nvidia’s most-awaited products in 2016 and the latest news adds more to the excitement caused by its impending release.

On 24 February, NVIDIA Corporation (NASDAQ:NVDA) shares moved up 0.70% and was closed at $31.82. NVDA EPS growth in last 5 year was 20.20%. NVIDIA Corporation (NASDAQ:NVDA) year to date (YTD) performance is -3.46%.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in ACADIA’s New Drug Application (NDA) for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. The Advisory Committee Meeting is scheduled for March 29, 2016.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ended the last trading day at $19.12. Company weekly volatility is calculated as 7.80% and price to cash ratio as 8.84. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) showed a weekly performance of -7.27%.

Leave a Reply

Your email address will not be published. Required fields are marked *